Variant-specific therapy for long QT syndrome type 3
- PMID: 36806575
- PMCID: PMC10913134
- DOI: 10.1016/j.hrthm.2023.02.013
Variant-specific therapy for long QT syndrome type 3
Comment on
-
Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.Heart Rhythm. 2023 May;20(5):709-717. doi: 10.1016/j.hrthm.2023.01.032. Epub 2023 Jan 31. Heart Rhythm. 2023. PMID: 36731785
References
-
- Wehrens XH, Vos MA, Doevendans PA, Wellens HJ. Novel insights in the congenital long QT syndrome. Ann Intern Med 2002;137:981–992. - PubMed
-
- Bennett PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995;376:683–685. - PubMed
-
- Wehrens XH, Abriel H, Cabo C, Benhorin J, Kass RS. Arrhythmogenic mechanism of an LQT-3 mutation of the human heart Na(+) channel alpha-subunit: a computational analysis. Circulation 2000;102:584–590. - PubMed
-
- Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2018;138:e272–e391. - PubMed
-
- Stutzman MJ, Gao X, Kim M, et al. Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies. Heart Rhythm 202X; XX:XXXXXX. - PubMed
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
